Why Amyloid-Beta Conformational Species—Not Plaques—Are the Central Battleground

The post-lecanemab competitive landscape for early Alzheimer’s disease is defined not by whether to target amyloid-beta (Aβ), but by which conformational species to target. A 2021 analysis from Alzheon, Inc. argued that “only agents that target soluble Aβ oligomers show clinical efficacy in AD patients” and that “clearance of amyloid plaque does not correlate with clinical improvements”—framing neurotoxic soluble Aβ oligomers as the upstream pathogenic drivers rather than fibrillar deposits. This argument retrospectively explains why earlier antibodies targeting primarily monomers or insoluble fibrils failed to produce clinical benefit, and it sets the mechanistic framework within which all next-generation agents—including remternetug (LY3372993)—are now evaluated.

The dataset identifies four primary Aβ structural variants as active therapeutic targets. Aβ protofibrils are the dominant target of lecanemab; pyroglutamate-modified Aβ (AβpE3) is the specific epitope of donanemab; soluble Aβ oligomers (AβOs) are the focus of ACU193 and ALZ-201; and the N-terminal Aβ4-x species is co-targeted by experimental agents such as NT4X. A 2023 meta-analysis from Guangdong Provincial Hospital provides the most systematic framework for linking epitope domain—N-terminal, C-terminal, central, or combined—to clinical outcomes, directly informing competitive positioning of remternetug versus its rivals.

Upstream molecular context involves amyloid precursor protein (APP) processing via BACE1 and γ-secretase, both represented in the literature as intervention points. However, immunotherapy approaches have largely superseded secretase inhibitors in the early AD setting, following a series of high-profile BACE1 inhibitor failures documented by regulatory agencies and reported extensively in the scientific literature.

Lecanemab and Donanemab Set the Clinical Benchmarks Every Successor Must Beat

Lecanemab (BAN2401), developed by Eisai, is the most clinically validated anti-amyloid antibody in this dataset. Its Phase 2b trial (NCT01767311) enrolled 856 subjects with early Alzheimer’s disease—comprising MCI due to AD and mild AD dementia—using a Bayesian adaptive randomization design across five dose regimens, with ADCOMS as the primary endpoint. Bayesian primary analysis at 12 months and frequentist analyses at 18 months across CDR-SB, ADAS-Cog14, and ADCOMS all showed directionally consistent effects, as documented by Berry Consultants, LLC. Open-label extension data from Eisai demonstrate “robust brain fibrillar amyloid reduction and slowing of clinical decline” with durability of effects following an off-treatment gap period. The Corewell Health review (2023) explicitly records FDA approval of lecanemab in January 2023 based on Phase 2 results, followed by Phase 3 confirmation—a regulatory milestone that validated the protofibril-targeting hypothesis for the field.

Donanemab targets a structurally distinct epitope: pyroglutamate-modified Aβ (AβpE3), an N-terminally truncated species described by Göttingen University as “abundantly present in the brain of AD patients” that “forms stable and soluble low-molecular weight oligomers and induces neurodegeneration in AD mouse models.” Its Phase 2 plaque clearance and cognitive stabilization results were characterised as a paradigm shift for AβpE3 as a drug target. Topline Phase 3 results released in May 2023 placed donanemab alongside lecanemab as a second confirmed disease-modifying agent—the only two in the class at that point.

“Agents that predominantly target amyloid monomers or plaque failed to show clinical effects, while agents targeting soluble Aβ oligomers show clinical efficacy in AD patients.”

Aducanumab, developed by Biogen, received FDA accelerated approval in June 2021 and is characterized in multiple retrieved papers as “the first drug with a putative disease-modifying mechanism” for Alzheimer’s disease. However, its approval was contested in terms of clinical effect size, distinguishing it from the more unequivocal efficacy signals of lecanemab and donanemab. Gantenerumab, developed by F. Hoffmann-La Roche, demonstrated robust pharmacodynamic target engagement—centiloid reductions of up to -90.3 centiloids from baseline over 36 months at subcutaneous doses up to 1200 mg every 4 weeks—but subsequently reported Phase 3 futility, underscoring that amyloid reduction alone does not guarantee clinical benefit. According to EMA and FDA guidance frameworks, the field has progressively moved toward requiring both amyloid biomarker change and clinical outcome evidence for full approval.

How Remternetug and Oligomer-Selective Agents Are Seeking Differentiation

Remternetug (LY3372993), Eli Lilly’s next-generation anti-amyloid antibody, is positioned within the pyroglutamate/N-terminal targeting paradigm that also encompasses donanemab. While remternetug is not individually cited by name in the retrieved clinical dataset, its competitive context is established through Eli Lilly’s broader immunotherapy portfolio and the N-terminal targeting strategy documented in the 2023 Guangdong Provincial Hospital meta-analysis, which systematically links epitope domain to clinical outcomes across the mAb class. A 2014 Eli Lilly immunotherapy review provides the earliest commercial anchor for the company’s sustained investment in this space.

The most structurally differentiated next-generation approach comes from oligomer-selective antibodies. ACU193, developed by Acumen Pharmaceuticals, is described as specifically targeting soluble Aβ oligomers rather than monomers or plaques—positioned as “an immunotherapeutic poised to test the amyloid β oligomer hypothesis.” Northwestern University researchers have demonstrated that AβO-selective antibodies can distinguish 5xFAD mouse models from wild-type mice by PET and MRI, establishing dual therapeutic and diagnostic potential. The 2006 University of Pennsylvania study showed that NAB61, a conformation-selective mAb targeting oligomeric Aβ structures, improved spatial learning and memory in aged Tg2576 mice—providing early preclinical proof of concept for the oligomer-selective approach.

ALZ-201, developed by Alzinova AB using oligomer-stabilizing technology, targets Aβ42 oligomers specifically and demonstrated reduction of neurotoxicity in primary mouse neuron cultures using Alzheimer’s disease patient brain extracts. The NT4X antibody, developed with Medical Research Council Technology, reacts with “both the free N-terminus of Aβ4-x and pyroglutamate Aβ3-X”—a dual-epitope approach that may offer broader coverage of the toxic Aβ species spectrum. As noted by WIPO in its annual IP statistics, antibody-based therapeutics consistently represent one of the fastest-growing patent filing categories in the neurology and neurodegenerative disease space.

The crenezumab CSF data from Genentech/Roche’s ABBY and BLAZE Phase 2 trials remain the only retrieved evidence showing direct human CSF oligomeric Aβ reduction for a clinical-stage antibody—with 89% of subcutaneous and 86% of IV-treated patients demonstrating lower oAβ levels at week 69 versus baseline, measured by ultrasensitive immunoassay. This establishes a translational biomarker precedent that next-generation oligomer-targeting agents, including ACU193, are expected to replicate and extend.

ARIA Safety Dynamics and the APOE4 Stratification Challenge

Amyloid-Related Imaging Abnormalities (ARIA) represent the primary safety constraint across the entire anti-amyloid antibody class. A 2018 Yale University review explicitly characterizes ARIA as “the major problems with safety” for anti-Aβ monoclonal antibodies. The mechanism is well-established: antibody-mediated amyloid clearance, particularly from cerebral vessel walls, triggers vascular inflammation and microhemorrhage detectable on MRI as ARIA-E (edema) and ARIA-H (hemosiderin deposition). Antibody design choices—including Fc engineering, isotype selection, and epitope targeting—all modulate ARIA risk profiles, as documented in a Lundbeck comparative preclinical study of bapineuzumab, crenezumab, and gantenerumab in the same transgenic model.

This APOE4 paradox is one of the most consequential design challenges for remternetug and successor agents. Enriching for APOE4 carriers maximises the probability of detecting an efficacy signal—consistent with the higher oligomer burden in this population—but simultaneously elevates the ARIA safety signal that regulatory agencies and clinical investigators must manage. Multiple retrieved papers reinforce this tension, and it is expected to drive differential dosing protocols, MRI monitoring schedules, and potentially APOE4-stratified labelling for next-generation approvals. Regulatory bodies including EMA have increasingly incorporated ARIA management guidance into approval conditions for this drug class.

“ARIA remains the major safety problem for anti-amyloid monoclonal antibodies—and antibody design choices including Fc engineering, isotype selection, and epitope targeting all influence individual risk profiles.”

The epitope-ARIA relationship also has direct IP implications. Antibodies targeting vascular Aβ deposits (such as those with high plaque affinity) tend to produce more ARIA than those selective for soluble species. This distinction is mechanistically relevant for remternetug’s positioning: if its N-terminal/AβpE3 targeting profile produces a more favourable ARIA risk-benefit ratio than lecanemab’s protofibril-targeting approach, that difference could constitute a clinically meaningful and commercially protectable differentiation—particularly for APOE4-positive patient populations.

Biomarker Stratification, TREM2 Augmentation, and the Combination Horizon

The next competitive frontier for remternetug and its successors is not just efficacy but the richness of the biomarker and combination strategy package surrounding each antibody. A 2020 CTAD Task Force paper from Brown University identifies “developing a better understanding of the specific amyloid species targeted by different antibodies” and “implementing more comprehensive repertoires of biomarkers” as the critical advances needed for next-generation trial success. This signals that next-generation agents will require plasma Aβ, tau, amyloid PET, and CSF oligomeric Aβ packages to achieve competitive clinical and commercial differentiation—not just amyloid clearance data.

TREM2 Microglial Augmentation

A mechanistically important finding from Ludwig-Maximilians-University Munich demonstrates that TREM2 deficiency reduces the efficacy of anti-Aβ antibody-mediated plaque clearance. Anti-amyloid antibodies stimulate Aβ uptake via Fc receptor-mediated phagocytosis, and “TREM2-deficient microglia show reduced capacity” for this response. This positions TREM2 agonists and microglial activators as logical combination partners for agents like remternetug that depend on Fc-mediated clearance mechanisms—and opens a patent space around combination regimens that is currently underexplored relative to the monotherapy filings dominating the retrieved dataset.

Dual Aβ + Tau Immunotherapy

A 2014 University of California San Diego paper explicitly proposes that “the next generation of immunotherapy for AD may involve the marriage of anti-Aβ antibodies” with tau-targeting agents. A 2022 Shanghai paper reinforces this, noting that “immunotherapeutic strategies targeting amyloid-β (Aβ) and tau proteins” represent the dominant combination hypothesis in the field. The commercial and IP implications are significant: combination regimens would require co-development agreements, shared biomarker endpoints, and potentially new composite clinical outcome measures—all areas where early patent positioning confers durable competitive advantage. As tracked by ClinicalTrials.gov, several dual-pathway trials are already in registration or early recruitment phases.

Assignee Landscape and IP Positioning

The retrieved dataset is entirely literature-driven—no patent filings are present—reflecting academic and clinical publication activity rather than commercial IP filing. The dominant commercial assignees are Eisai (lecanemab clinical data), F. Hoffmann-La Roche/Genentech (gantenerumab and crenezumab data), and Eli Lilly (contextual immunotherapy review). Emerging biotech assignees include Acumen Pharmaceuticals (ACU193), Alzinova AB (ALZ-201), and Alzheon (oligomer inhibitor program). Academic institutions with active authorship include UCL Queen Square Institute of Neurology, Washington University School of Medicine, Yale University, Northwestern University, University of Pennsylvania, and multiple European centers. The absence of patent data in this snapshot means that the full IP competitive landscape—including composition-of-matter claims, method-of-treatment filings, and biomarker-use patents—requires dedicated patent search to assess, a capability available through PatSnap Eureka.